Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Digoxin | Digoxin may decrease the cardiotoxic activities of Paclitaxel poliglumex. |
| Acetyldigitoxin | Acetyldigitoxin may decrease the cardiotoxic activities of Paclitaxel poliglumex. |
| Deslanoside | Deslanoside may decrease the cardiotoxic activities of Paclitaxel poliglumex. |
| Ouabain | Ouabain may decrease the cardiotoxic activities of Paclitaxel poliglumex. |
| Digitoxin | Digitoxin may decrease the cardiotoxic activities of Paclitaxel poliglumex. |
| Oleandrin | Oleandrin may decrease the cardiotoxic activities of Paclitaxel poliglumex. |
| Cymarin | Cymarin may decrease the cardiotoxic activities of Paclitaxel poliglumex. |
| Proscillaridin | Proscillaridin may decrease the cardiotoxic activities of Paclitaxel poliglumex. |
| Metildigoxin | Metildigoxin may decrease the cardiotoxic activities of Paclitaxel poliglumex. |
| Lanatoside C | Lanatoside C may decrease the cardiotoxic activities of Paclitaxel poliglumex. |
| Gitoformate | Gitoformate may decrease the cardiotoxic activities of Paclitaxel poliglumex. |
| Acetyldigoxin | Acetyldigoxin may decrease the cardiotoxic activities of Paclitaxel poliglumex. |
| Peruvoside | Peruvoside may decrease the cardiotoxic activities of Paclitaxel poliglumex. |
| Peginterferon alfa-2a | The risk or severity of cardiotoxicity can be increased when Peginterferon alfa-2a is combined with Paclitaxel poliglumex. |
| Trastuzumab | The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Paclitaxel poliglumex. |
| Bevacizumab | The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Paclitaxel poliglumex. |
| Bortezomib | The risk or severity of cardiotoxicity can be increased when Bortezomib is combined with Paclitaxel poliglumex. |
| Cladribine | The risk or severity of cardiotoxicity can be increased when Cladribine is combined with Paclitaxel poliglumex. |
| Carmustine | The risk or severity of cardiotoxicity can be increased when Carmustine is combined with Paclitaxel poliglumex. |
| Amsacrine | The risk or severity of cardiotoxicity can be increased when Amsacrine is combined with Paclitaxel poliglumex. |
| Bleomycin | The risk or severity of cardiotoxicity can be increased when Bleomycin is combined with Paclitaxel poliglumex. |
| Mitomycin | The risk or severity of cardiotoxicity can be increased when Mitomycin is combined with Paclitaxel poliglumex. |
| Vindesine | The risk or severity of cardiotoxicity can be increased when Vindesine is combined with Paclitaxel poliglumex. |
| Vinorelbine | The risk or severity of cardiotoxicity can be increased when Vinorelbine is combined with Paclitaxel poliglumex. |
| Teniposide | The risk or severity of cardiotoxicity can be increased when Teniposide is combined with Paclitaxel poliglumex. |
| Epirubicin | The risk or severity of cardiotoxicity can be increased when Epirubicin is combined with Paclitaxel poliglumex. |
| Cisplatin | The risk or severity of cardiotoxicity can be increased when Cisplatin is combined with Paclitaxel poliglumex. |
| Cyclophosphamide | The risk or severity of cardiotoxicity can be increased when Cyclophosphamide is combined with Paclitaxel poliglumex. |
| Vincristine | The risk or severity of cardiotoxicity can be increased when Vincristine is combined with Paclitaxel poliglumex. |
| Fluorouracil | The risk or severity of cardiotoxicity can be increased when Fluorouracil is combined with Paclitaxel poliglumex. |
| Pentostatin | The risk or severity of cardiotoxicity can be increased when Pentostatin is combined with Paclitaxel poliglumex. |
| Methotrexate | The risk or severity of cardiotoxicity can be increased when Methotrexate is combined with Paclitaxel poliglumex. |
| Vinblastine | The risk or severity of cardiotoxicity can be increased when Vinblastine is combined with Paclitaxel poliglumex. |
| Imatinib | The risk or severity of cardiotoxicity can be increased when Imatinib is combined with Paclitaxel poliglumex. |
| Tamoxifen | The risk or severity of cardiotoxicity can be increased when Tamoxifen is combined with Paclitaxel poliglumex. |
| Daunorubicin | The risk or severity of cardiotoxicity can be increased when Daunorubicin is combined with Paclitaxel poliglumex. |
| Tretinoin | The risk or severity of cardiotoxicity can be increased when Tretinoin is combined with Paclitaxel poliglumex. |
| Etoposide | The risk or severity of cardiotoxicity can be increased when Etoposide is combined with Paclitaxel poliglumex. |
| Mechlorethamine | The risk or severity of cardiotoxicity can be increased when Mechlorethamine is combined with Paclitaxel poliglumex. |
| Doxorubicin | The risk or severity of cardiotoxicity can be increased when Doxorubicin is combined with Paclitaxel poliglumex. |
| Busulfan | The risk or severity of cardiotoxicity can be increased when Busulfan is combined with Paclitaxel poliglumex. |
| Thalidomide | The risk or severity of cardiotoxicity can be increased when Thalidomide is combined with Paclitaxel poliglumex. |
| Fludarabine | The risk or severity of cardiotoxicity can be increased when Fludarabine is combined with Paclitaxel poliglumex. |
| Capecitabine | The risk or severity of cardiotoxicity can be increased when Capecitabine is combined with Paclitaxel poliglumex. |
| Arsenic trioxide | The risk or severity of cardiotoxicity can be increased when Arsenic trioxide is combined with Paclitaxel poliglumex. |
| Idarubicin | The risk or severity of cardiotoxicity can be increased when Idarubicin is combined with Paclitaxel poliglumex. |
| Ifosfamide | The risk or severity of cardiotoxicity can be increased when Ifosfamide is combined with Paclitaxel poliglumex. |
| Mitoxantrone | The risk or severity of cardiotoxicity can be increased when Mitoxantrone is combined with Paclitaxel poliglumex. |
| Anastrozole | The risk or severity of cardiotoxicity can be increased when Anastrozole is combined with Paclitaxel poliglumex. |
| Paclitaxel | The risk or severity of cardiotoxicity can be increased when Paclitaxel is combined with Paclitaxel poliglumex. |
| Docetaxel | The risk or severity of cardiotoxicity can be increased when Docetaxel is combined with Paclitaxel poliglumex. |
| Aldoxorubicin | The risk or severity of cardiotoxicity can be increased when Aldoxorubicin is combined with Paclitaxel poliglumex. |
| Paclitaxel trevatide | The risk or severity of cardiotoxicity can be increased when Paclitaxel trevatide is combined with Paclitaxel poliglumex. |
| Cabazitaxel | The risk or severity of cardiotoxicity can be increased when Cabazitaxel is combined with Paclitaxel poliglumex. |
| Pertuzumab | The risk or severity of cardiotoxicity can be increased when Pertuzumab is combined with Paclitaxel poliglumex. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Paclitaxel poliglumex. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Paclitaxel poliglumex. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Paclitaxel poliglumex. |
| Methoxy polyethylene glycol-epoetin beta | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Paclitaxel poliglumex. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Lidocaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Ropivacaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Bupivacaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Cinchocaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Dyclonine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Procaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Prilocaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Proparacaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Meloxicam. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Oxybuprocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Cocaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Mepivacaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Levobupivacaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Diphenhydramine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Benzocaine. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Chloroprocaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Phenol. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Tetrodotoxin. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Benzyl alcohol. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Capsaicin. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Etidocaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Articaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Tetracaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Propoxycaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Pramocaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Butamben. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Butacaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Oxetacaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Ethyl chloride. |
| Butanilicaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Butanilicaine. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Quinisocaine. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Paclitaxel poliglumex. |
| Ambroxol | The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Ambroxol. |
| Etrasimod | The risk or severity of immunosuppression can be increased when Paclitaxel poliglumex is combined with Etrasimod. |